Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1005
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Colorado Anschutz, Aurora, CO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Colorado Anschutz, Aurora, CO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 985–996 of 1,005 matching trials with a site at University of Colorado Anschutz, Aurora, CO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

NCT05293626
Site status not listed — check the official record
Conditions
Leber Hereditary Optic Neuropathy (LHON)
Interventions
NR082 Injection, Injection needle
Drug · Device
Lead sponsor
Neurophth Therapeutics Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania
Recruiting No phase listed Observational

Epilepsy Learning Healthcare System (ELHS)

NCT06265103
Status at this site: Recruiting
Conditions
Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
Interventions
Clinical care and quality improvement
Other
Lead sponsor
Epilepsy Foundation of America
Other
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2099
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Recruiting Not applicable Interventional

PCOM2 - The Physician Communication Intervention, Version 2.0

NCT05336240
Status at this site: Recruiting
Conditions
HPV Infection, Preventive Health Services
Interventions
Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Wichita, Kansas
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of THC on Alcohol Consumption and Neural Correlates of Reward

NCT06446479
Status at this site: Recruiting
Conditions
Cannabis Use Disorder
Interventions
Dronabinol Pill, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 40 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Active, not recruiting No phase listed Observational

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

NCT04091984
Site status not listed — check the official record
Conditions
Kidney Transplant Rejection
Interventions
Prospera
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice

NCT05877391
Status at this site: Recruiting
Conditions
Sexual and Gender Minorities, Hospice, Alzheimer's Disease and Related Dementias
Interventions
SGM Communication Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
Status at this site: Recruiting
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Knee Arthroplasty, Total
Interventions
Truliant Total Knee System
Device
Lead sponsor
Exactech
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
5
States / cities
Aurora, Colorado • DeLand, Florida • Las Vegas, Nevada + 2 more
Active, not recruiting Phase 1 Interventional

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

NCT02293980
Site status not listed — check the official record
Conditions
ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Interventions
MK-3795, Nivolumab, Cabozantinib, Bezlutifan
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
25
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 18 more
Recruiting No phase listed Observational

Prospective Evaluation of the Efficacy and Safety of Endoscopic Tissue Apposition

NCT03626194
Status at this site: Recruiting
Conditions
Endoscopic Tissue Apposition, Endoscopic Suturing, Endoscopic Clipping, Bariatric Endoscopy, Transoral Outlet Reduction, Endoscopic Sleeve Gastroplasty
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Rheumatoid Arthritis, Interstitial Lung Disease
Interventions
Research Testing Performed (Laboratory), Information Collected as Standard of Care, Research Testing Performed
Genetic · Diagnostic Test · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Kansas City, Kansas + 1 more
Conditions
Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
regional nodal XRT, chestwall XRT, WBI
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
489
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more

About this University of Colorado Anschutz institution page

What this page lists
ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.